» Articles » PMID: 37540289

Circulating MicroRNAs Can Predict Chemotherapy-induced Toxicities in Patients Being Treated for Primary Breast Cancer

Abstract

Purpose: Prescribing NAC for breast cancer is a pragmatic treatment strategy for several reasons; however, certain patients suffer chemotherapy-induced toxicities. Unfortunately, identifying patients at risk of toxicity often proves challenging. MiRNAs are small non-coding RNA molecules which modulate genetic expression. The aim of this study was to determine whether circulating miRNAs are sensitive biomarkers that can identify the patients likely to suffer treatment-related toxicities to neoadjuvant chemotherapy (NAC) for primary breast cancer.

Methods: This secondary exploratory from the prospective, multicentre translational research trial (CTRIAL ICORG10/11-NCT01722851) recruited 101 patients treated with NAC for breast cancer, from eight treatment sites across Ireland. A predetermined five miRNAs panel was quantified using RQ-PCR from patient bloods at diagnosis. MiRNA expression was correlated with chemotherapy-induced toxicities. Regression analyses was performed using SPSS v26.0.

Results: One hundred and one patients with median age of 55 years were recruited (range: 25-76). The mean tumour size was 36 mm and 60.4% had nodal involvement (n = 61) Overall, 33.7% of patients developed peripheral neuropathies (n = 34), 28.7% developed neutropenia (n = 29), and 5.9% developed anaemia (n = 6). Reduced miR-195 predicted patients likely to develop neutropenia (P = 0.048), while increased miR-10b predicted those likely to develop anaemia (P = 0.049). Increased miR-145 predicted those experiencing nausea and vomiting (P = 0.019), while decreased miR-21 predicted the development of mucositis (P = 0.008).

Conclusion: This is the first study which illustrates the value of measuring circulatory miRNA to predict patient-specific toxicities to NAC. These results support the ideology that circulatory miRNAs are biomarkers with utility in predicting chemotherapy toxicity as well as treatment response.

Citing Articles

Gelatin-Oxidized Alginate and Chitosan-Coated Zein Nanoparticle Hydrogel Composite to Enhance Breast Cancer Cytotoxicity in Dual-Drug Delivery.

Nascimento S, de Souza R, Sobral M, Xavier-Junior F, da Silva M, Viana M ACS Omega. 2024; 9(45):45190-45202.

PMID: 39554428 PMC: 11561619. DOI: 10.1021/acsomega.4c06404.


MicroRNA signatures in osteosarcoma: diagnostic insights and therapeutic prospects.

Dey M, Skipar P, Bartnik E, Piatkowski J, Sulejczak D, Czarnecka A Mol Cell Biochem. 2024; .

PMID: 39419925 DOI: 10.1007/s11010-024-05135-5.


Molecular Morbidity Score-Can MicroRNAs Assess the Burden of Disease?.

Butler T, Davey M, Kerin M Int J Mol Sci. 2024; 25(15).

PMID: 39125612 PMC: 11312210. DOI: 10.3390/ijms25158042.


MicroRNAs as Molecular Biomarkers for the Characterization of Basal-like Breast Tumor Subtype.

Tariq M, Richard V, Kerin M Biomedicines. 2023; 11(11).

PMID: 38002007 PMC: 10669494. DOI: 10.3390/biomedicines11113007.

References
1.
Burstein H, Curigliano G, Thurlimann B, Weber W, Poortmans P, Regan M . Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021; 32(10):1216-1235. PMC: 9906308. DOI: 10.1016/j.annonc.2021.06.023. View

2.
Mauri D, Pavlidis N, Ioannidis J . Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005; 97(3):188-94. DOI: 10.1093/jnci/dji021. View

3.
Schott A, Hayes D . Defining the benefits of neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2012; 30(15):1747-9. DOI: 10.1200/JCO.2011.41.3161. View

4.
Davey M, Browne F, Miller N, Lowery A, Kerin M . Pathological complete response as a surrogate to improved survival in human epidermal growth factor receptor-2-positive breast cancer: systematic review and meta-analysis. BJS Open. 2022; 6(3). PMC: 9071230. DOI: 10.1093/bjsopen/zrac028. View

5.
Behranvand N, Nasri F, Zolfaghari Emameh R, Khani P, Hosseini A, Garssen J . Chemotherapy: a double-edged sword in cancer treatment. Cancer Immunol Immunother. 2021; 71(3):507-526. PMC: 10992618. DOI: 10.1007/s00262-021-03013-3. View